Ovarian Cancer Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Ovarian Cancer.
Found 9 Approved Drugs for Ovarian Cancer
CISplatin
Generic Name
CISplatin
CISplatin
Generic Name
CISplatin
Form: Injection
Method of administration: Intravenous
FDA approval date: June 01, 2000
Classification: Platinum-based Drug
Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy.
DOXOrubicin
Brand Names
Doxil, Adriamycin
DOXOrubicin
Brand Names
Doxil, Adriamycin
Form: Injection, Injectable
Method of administration: Intravenous, Intravitreal
FDA approval date: December 23, 1987
Classification: Anthracycline Topoisomerase Inhibitor
Doxorubicin is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer.
Bevacizumab
Brand Names
Zirabev, Avastin, MVASI, Alymsys, Vegzelma
Bevacizumab
Brand Names
Zirabev, Avastin, MVASI, Alymsys, Vegzelma
Form: Injection
Method of administration: Intravenous
FDA approval date: February 26, 2004
Classification: Vascular Endothelial Growth Factor Inhibitor
MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
Gemcitabine
Generic Name
Gemcitabine
Gemcitabine
Generic Name
Gemcitabine
Form: Injection
Method of administration: Intravenous
FDA approval date: November 15, 2010
Classification: Nucleoside Metabolic Inhibitor
Gemcitabine for Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
Hycamtin
Generic Name
Topotecan
Hycamtin
Generic Name
Topotecan
Form: Injection, Capsule
Method of administration: Oral, Intravenous
FDA approval date: November 30, 2010
Classification: Topoisomerase Inhibitor
HYCAMTIN ® capsules are indicated for the treatment of relapsed small cell lung cancer (SCLC) in patients with a prior complete or partial response and who are at least 45 days from the end of first-line chemotherapy. HYCAMTIN capsules is a topoisomerase inhibitor indicated for treatment of patients with relapsed small cell lung cancer (SCLC). ( 1 )
Showing 1-5 of 9
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances